Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of Hepatitis C Virus-Infected Cells and Liver to Identify Pathways Associated With Disease Development.

BACKGROUND & AIMS The mechanisms of hepatitis C virus (HCV) infection, liver disease progression, and hepatocarcinogenesis are only partially understood. We performed genomic, proteomic, and metabolomic analyses of HCV-infected cells and chimeric mice to learn more about these processes. METHODS Huh7.5.1dif (hepatocyte-like cells) were infected with culture-derived HCV and used in RNA sequencing, proteomic, metabolomic, and integrative genomic analyses. uPA/SCID (urokinase-type plasminogen activator/severe combined immunodeficiency) mice were injected with serum from HCV-infected patients; 8 weeks later, liver tissues were collected and analyzed by RNA sequencing and proteomics. Using differential expression, gene set enrichment analyses, and protein interaction mapping, we identified pathways that changed in response to HCV infection. We validated our findings in studies of liver tissues from 216 patients with HCV infection and early-stage cirrhosis and paired biopsy specimens from 99 patients with hepatocellular carcinoma, including 17 patients with histologic features of steatohepatitis. Cirrhotic liver tissues from patients with HCV infection were classified into 2 groups based on relative peroxisome function; outcomes assessed included Child-Pugh class, development of hepatocellular carcinoma, survival, and steatohepatitis. Hepatocellular carcinomas were classified according to steatohepatitis; the outcome was relative peroxisomal function. RESULTS We quantified 21,950 messenger RNAs (mRNAs) and 8297 proteins in HCV-infected cells. Upon HCV infection of hepatocyte-like cells and chimeric mice, we observed significant changes in levels of mRNAs and proteins involved in metabolism and hepatocarcinogenesis. HCV infection of hepatocyte-like cells significantly increased levels of the mRNAs, but not proteins, that regulate the innate immune response; we believe this was due to the inhibition of translation in these cells. HCV infection of hepatocyte-like cells increased glucose consumption and metabolism and the STAT3 signaling pathway and reduced peroxisome function. Peroxisomes mediate β-oxidation of very-long-chain fatty acids; we found intracellular accumulation of very-long-chain fatty acids in HCV-infected cells, which is also observed in patients with fatty liver disease. Cells in livers from HCV-infected mice had significant reductions in levels of the mRNAs and proteins associated with peroxisome function, indicating perturbation of peroxisomes. We found that defects in peroxisome function were associated with outcomes and features of HCV-associated cirrhosis, fatty liver disease, and hepatocellular carcinoma in patients. CONCLUSIONS We performed combined transcriptome, proteome, and metabolome analyses of liver tissues from HCV-infected hepatocyte-like cells and HCV-infected mice. We found that HCV infection increases glucose metabolism and the STAT3 signaling pathway and thereby reduces peroxisome function; alterations in the expression levels of peroxisome genes were associated with outcomes of patients with liver diseases. These findings provide insights into liver disease pathogenesis and might be used to identify new therapeutic targets.

[1]  Philippe Lefebvre,et al.  Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. , 2015, Journal of hepatology.

[2]  T. Fujiwara,et al.  PI4K-beta and MKNK1 are regulators of hepatitis C virus IRES-dependent translation , 2015, Scientific Reports.

[3]  G. Brooks,et al.  Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg Effect , 2016, Carcinogenesis.

[4]  François-Loïc Cosset,et al.  HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. , 2013, Cell host & microbe.

[5]  Marcel Martin Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .

[6]  G. Farrell,et al.  Epidemiology of non-alcoholic fatty liver disease in China. , 2009, Journal of hepatology.

[7]  Se-Jin Kim,et al.  Catalase inhibition induces pexophagy through ROS accumulation. , 2018, Biochemical and biophysical research communications.

[8]  S. Sze,et al.  Hypoxia Activated EGFR Signaling Induces Epithelial to Mesenchymal Transition (EMT) , 2012, PloS one.

[9]  A. Necsulea,et al.  Transcriptional response to hepatitis C virus infection and interferon‐alpha treatment in the human liver , 2017, EMBO molecular medicine.

[10]  R. Deberardinis,et al.  The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid β-oxidation , 2005, Oncogene.

[11]  Sander Kersten,et al.  Roles of PPARs in health and disease , 2000, Nature.

[12]  M. Imamura,et al.  HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response , 2019, Gastroenterology.

[13]  A. C. Könner,et al.  Toll-like receptors: linking inflammation to metabolism , 2011, Trends in Endocrinology & Metabolism.

[14]  R. Bartenschlager,et al.  Hepatitis C Virus RNA Replication and Assembly: Living on the Fat of the Land , 2014, Cell Host & Microbe.

[15]  S. Lemon,et al.  Regulating Intracellular Antiviral Defense and Permissiveness to Hepatitis C Virus RNA Replication through a Cellular RNA Helicase, RIG-I , 2005, Journal of Virology.

[16]  E. Schiff,et al.  Hepatitis B Virus and DNA Stimulation Trigger a Rapid Innate Immune Response through NF-κB , 2016, The Journal of Immunology.

[17]  Christina Leslie,et al.  An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions. , 2012, Cell host & microbe.

[18]  P. Schirmacher,et al.  Control of temporal activation of hepatitis C virus-induced interferon response by domain 2 of nonstructural protein 5A. , 2015, Journal of hepatology.

[19]  N. Braverman,et al.  Peroxisome‐Mediated Metabolism Is Required for Immune Response to Microbial Infection , 2017, Immunity.

[20]  D. Burton,et al.  Robust hepatitis C virus infection in vitro. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. Shavinskaya,et al.  Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[22]  C. Semenkovich,et al.  Peroxisomes: a nexus for lipid metabolism and cellular signaling. , 2014, Cell metabolism.

[23]  M. Binder,et al.  Secretion of Hepatitis C Virus Replication Intermediates Reduces Activation of Toll-Like Receptor 3 in Hepatocytes. , 2018, Gastroenterology.

[24]  N. Pochet,et al.  Module Analysis Captures Pancancer Genetically and Epigenetically Deregulated Cancer Driver Genes for Smoking and Antiviral Response , 2017, bioRxiv.

[25]  M. Binder,et al.  Hepatitis C virus escape from the interferon regulatory factor 3 pathway by a passive and active evasion strategy , 2007, Hepatology.

[26]  A. Regev,et al.  Preparation of Single‐Cell RNA‐Seq Libraries for Next Generation Sequencing , 2014, Current protocols in molecular biology.

[27]  H. Kwon,et al.  Hostile takeovers: viral appropriation of the NF-kB pathway , 2001 .

[28]  R. Bartenschlager,et al.  The lipid droplet is an important organelle for hepatitis C virus production , 2007, Nature Cell Biology.

[29]  Qibin Zhang,et al.  Temporal Proteome and Lipidome Profiles Reveal Hepatitis C Virus-Associated Reprogramming of Hepatocellular Metabolism and Bioenergetics , 2010, PLoS pathogens.

[30]  B. Neuschwander‐Tetri,et al.  Mechanisms of NAFLD development and therapeutic strategies , 2018, Nature Medicine.

[31]  Olivier Gevaert,et al.  MethylMix: an R package for identifying DNA methylation-driven genes , 2015, Bioinform..

[32]  N. Pochet,et al.  Hepatitis B virus evasion from cGAS sensing in human hepatocytes , 2018 .

[33]  R. Hamatake,et al.  Gene Expression Profiling Indicates the Roles of Host Oxidative Stress, Apoptosis, Lipid Metabolism, and Intracellular Transport Genes in the Replication of Hepatitis C Virus , 2010, Journal of Virology.

[34]  O. Weiland,et al.  Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. , 2017, Journal of hepatology.

[35]  Bin Zhang,et al.  Clinicopathological indices to predict hepatocellular carcinoma molecular classification , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[36]  V. Bajic,et al.  HCVpro: hepatitis C virus protein interaction database. , 2011, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[37]  Priya S. Shah,et al.  A combined proteomics/genomics approach links hepatitis C virus infection with nonsense-mediated mRNA decay. , 2015, Molecular cell.

[38]  Avi Ma'ayan,et al.  Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.

[39]  Q. Ding,et al.  MDA5 plays a critical role in interferon response during hepatitis C virus infection. , 2015, Journal of hepatology.

[40]  S. Plevritis,et al.  Identification of ovarian cancer driver genes by using module network integration of multi-omics data , 2013, Interface Focus.

[41]  F. Chisari,et al.  Production of Infectious Hepatitis C Virus by Well-Differentiated, Growth-Arrested Human Hepatoma-Derived Cells , 2006, Journal of Virology.

[42]  T. Baumert,et al.  Signaling of hepatitis C virus , 2015 .

[43]  Meijin Huang,et al.  Inhibition of miR‐148a‐3p resists hepatocellular carcinoma progress of hepatitis C virus infection through suppressing c‐Jun and MAPK pathway , 2018, Journal of cellular and molecular medicine.

[44]  R. Pugh,et al.  Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.

[45]  P. Schirmacher,et al.  Persistence of HCV in quiescent hepatic cells under conditions of an interferon-induced antiviral response. , 2012, Gastroenterology.

[46]  G. Stephanopoulos,et al.  Loss of RBF1 changes glutamine catabolism. , 2013, Genes & development.

[47]  J. Auwerx,et al.  Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. , 2005, Gastroenterology.

[48]  Thomas F. Baumert,et al.  Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral Agents , 2014, PLoS pathogens.

[49]  P. Chambon,et al.  Homeostasis in Intestinal Epithelium Is Orchestrated by the Circadian Clock and Microbiota Cues Transduced by TLRs , 2013, Cell.

[50]  D. Schwudke,et al.  Complex lipid metabolic remodeling is required for efficient hepatitis C virus replication. , 2018, Biochimica et biophysica acta. Molecular and cell biology of lipids.

[51]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[52]  Jacob D. Jaffe,et al.  Deep, Quantitative Coverage of the Lysine Acetylome Using Novel Anti-acetyl-lysine Antibodies and an Optimized Proteomic Workflow* , 2015, Molecular & Cellular Proteomics.

[53]  J. Hardwick,et al.  PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid ω-Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease , 2010, PPAR research.

[54]  M. Voiculescu,et al.  Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease. , 2015, European journal of internal medicine.

[55]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[56]  N. Pochet,et al.  miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis , 2017, Gut.

[57]  Maxwell R. Mumbach,et al.  Dynamic profiling of the protein life cycle in response to pathogens , 2015, Science.

[58]  F. Chisari,et al.  Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation. , 2009, Cell host & microbe.

[59]  R. Wanders,et al.  Gas chromatography/mass spectrometry analysis of very long chain fatty acids, docosahexaenoic acid, phytanic acid and plasmalogen for the screening of peroxisomal disorders , 2003, Brain and Development.

[60]  S. Gabriel,et al.  Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. , 2013, Gastroenterology.

[61]  Åsa K. Björklund,et al.  Full-length RNA-seq from single cells using Smart-seq2 , 2014, Nature Protocols.

[62]  Kenji Ikeda,et al.  Gene expression in fixed tissues and outcome in hepatocellular carcinoma. , 2008, The New England journal of medicine.

[63]  M. Hiet,et al.  Biochemical and Morphological Properties of Hepatitis C Virus Particles and Determination of Their Lipidome* , 2010, The Journal of Biological Chemistry.

[64]  Cameron J. Schweitzer,et al.  Hepatitis C virus depends on E-cadherin as an entry factor and regulates its expression in epithelial-to-mesenchymal transition , 2016, Proceedings of the National Academy of Sciences.

[65]  M. Fukayama,et al.  CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity , 2018, Gut.

[66]  G. Farrell,et al.  Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease. , 2018, Advances in experimental medicine and biology.

[67]  L. Knoll,et al.  Dual transcriptional profiling of mice and Toxoplasma gondii during acute and chronic infection , 2014, BMC Genomics.

[68]  Ralf Bartenschlager,et al.  Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81 , 2007, Hepatology.

[69]  J. Mesirov,et al.  GenePattern 2.0 , 2006, Nature Genetics.

[70]  K. Clément,et al.  Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity. , 2015, Journal of hepatology.

[71]  Olivier Poch,et al.  EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy , 2011, Nature Medicine.

[72]  Isabelle Robert,et al.  Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer , 2007, Proceedings of the National Academy of Sciences.

[73]  M. Prentki,et al.  Glucose Down-regulates the Expression of the Peroxisome Proliferator-activated Receptor-α Gene in the Pancreatic β-Cell* , 2000, The Journal of Biological Chemistry.

[74]  A. Subramanian,et al.  Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. , 2016, Cancer cell.

[75]  C. Rice,et al.  Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. , 2018, Virus research.